Navigation Links
BNA Books Announces the Publication of the 2011 Cumulative Supplement to "Pharmaceutical Law: Regulation of Research, Development, and Marketing"
Date:1/10/2012

ARLINGTON, Va., Jan. 10, 2012 /PRNewswire-USNewswire/ -- BNA Books, a division of specialized news and information publisher BNA, today announces the publication of the 2011 Cumulative Supplement to Pharmaceutical Law: Regulation of Research, Development, and Marketing, providing important updates on securities cases and developments involving fraud and abuse, HIPAA, and the FDA. The treatise is one of the many ABA/BNA publications available from BNA Books.

(Logo: http://photos.prnewswire.com/prnh/20120110/DC33627LOGO)

Pharmaceutical Law: Regulation of Research, Development, and Marketing is the only resource available that provides expert commentary and authoritative insights into a comprehensive range of pharmaceutical law issues. No other single volume discusses these complex issues in so much detail and offers the information required by transactional health care attorneys to adequately advise clients on the opportunities—and the liabilities—in this industry. This treatise addresses the considerable fraud-and-abuse risks unique to this submarket of the health care industry; covers off-label marketing—selling a drug for a purpose other than its intended use; and explains and discusses other hot risks areas, including the potential for antitrust, securities law, and other compliance violations.

The Medicare Part D drug benefit, coupled with the confusing and cumbersome methodology used for reimbursement, has added pressures to the already strained Medicare budget, increasing regulatory scrutiny and creating traps for the unwary and uninformed. Other increasingly important areas—including reimbursement and regulation, civil and regulatory liability under the securities and antitrust laws, and compliance and corporate governance issues—also are receiving increased attention from regulators.

The 2011 Cumulative Supplement includes discussion of:

  • The indictment of an FDA chemist for insider trading
  • Foreign Corrupt Practices Act enforcement action against Johnson & Johnson related to unlawful payments and kickbacks
  • The renewed importance of the Responsible Corporate Officer Doctrine
  • The 2010 Amendments to the Organizational Sentencing Guidelines and their impact on how companies can benefit by structuring their compliance programs in specific ways
  • The HITECH Act and its various requirements, including breach notification, restrictions on remuneration for PHI, and penalties
  • The heightened emphasis on HIPAA Enforcement
  • The Future of FDA Regulatory Authority and the FDA's Initiatives for 2011–2015
  • The expansion of FDA authority by Title VII of PPACA and the Biologics Price Competition and Innovation Act of 2009 (BPCIA) 

The treatise was published in cooperation with the ABA Health Law Section. Section publications provide a balanced forum for the views and professional development of practitioners in health law. For more information on Section participation, please call the Section at 312.988.5824 or visit www.americanbar.org/groups/health_law.html.

The editor-in-chief of Pharmaceutical Law: Regulation of Research, Development, and Marketing, 2011 Supplement is Michael E. Clark, Special Counsel with Duane Morris, LLP, Houston, TX, and Adjunct Professor of Law at the University of Houston Law Center, who previously served as Chief of the Criminal Division of the U.S. Attorney's Office for the Southern District of Texas.

BNA, a wholly-owned subsidiary of Bloomberg L.P., is a leading source of legal, regulatory, and business information for professionals. In addition to Pharmaceutical Law: Regulation of Research, Development, and Marketing, BNA's Book Division publishes: E-Health, Privacy, and Security Law; Health Care Fraud and Abuse: Practical Perspectives; Managed Care Litigation; Prosecuting and Defending Health Care Fraud Cases; and other titles in health law. For a free BNA Books catalog, call 1.800.960.1220, send an e-mail request to books@bna.com, or visit us online at www.bna.com/bnabooks.  

Pharmaceutical Law: Regulation of Research, Development, and Marketing, 2011 Supplement may be purchased alone (Order #1995-PR11/$230.00 plus tax, shipping, and handling) or with the main volume (Order #9995-PR11/$485.00 plus tax, shipping, and handling) from BNA Books, PO Box 7814, Edison, NJ 08818-7814. Telephone orders: 1.800.960.1220. Fax orders: 1.732.346.1624. A 10% discount is available on print copies of books when ordering from the website at www.bna.com/bnabooks.  Please note that discounts cannot be combined.

Editors: Review copy available upon request.
Please e-mail Matt Greene at mgreene@bna.com, or call 703.341.5767.


'/>"/>
SOURCE BNA Books
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
2. BNA Books Announces Publication of New 2009 Cumulative Supplement to Pharmaceutical Law: Regulation of Research, Development, and Marketing
3. Elsevier Appoints Suzanne BeDell as Managing Director, Science and Technology (S&T) Books
4. Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain
5. Cookstr Launches New Digital Recipe Collections Exclusively on Apples iBookstore
6. Varian Medical Systems Books $88 Million Order to Equip Proton Treatment Center
7. Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase
8. BNA Books Announces the Publication of the 2011 Supplement to "Pharmaceutical Patent Law, Second Edition"
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):